The FDA approved orforglipron (brand name Foundayo) on April 1, 2026 -- the first oral GLP-1 pill you can take at any time of day without food or water restrictions. It shipped in 50 days, making it the fastest novel molecular entity approval since 2002. For anyone currently using compounded semaglutide or tirzepatide injections, the question is obvious: should you switch?
The short answer: probably not yet. Here is why.
What the FDA Just Approved
Orforglipron is a small-molecule GLP-1 receptor agonist -- not a peptide. Unlike semaglutide and tirzepatide, which are peptide-based injectables, orforglipron survives stomach acid and absorbs orally. That is its primary technical advantage.
The approval covers adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, alongside reduced-calorie diet and increased physical activity.
Key trial data from the Phase 3 ATTAIN-1 study:
| Metric | Orforglipron (36mg) | Injectable Semaglutide (2.4mg) | Injectable Tirzepatide (15mg) |
|---|---|---|---|
| Avg. weight loss | ~12% at 72 weeks | ~15% at 68 weeks | ~20-22% at 72 weeks |
| Administration | Daily pill | Weekly injection | Weekly injection |
| Food restrictions | None | N/A (injectable) | N/A (injectable) |
| FDA approved | April 1, 2026 | Yes | Yes |
The head-to-head ACHIEVE-3 trial also showed orforglipron outperformed oral semaglutide on both weight loss and blood sugar control. But oral semaglutide has always been the weaker formulation -- the injectable version remains the clinical standard.
What This Means for Peptide Buyers
Here is the practical breakdown for anyone evaluating their options right now.
Price Comparison
| Option | Monthly Cost (Self-Pay) | Weight Loss | Route |
|---|---|---|---|
| Orforglipron (Foundayo) | $149-299/mo | ~12% | Daily pill |
| Compounded semaglutide | $129-299/mo | ~15% | Weekly injection |
| Compounded tirzepatide | $150-350/mo | ~20-22% | Weekly injection |
| Compounded retatrutide | $200-400/mo | ~24% | Weekly injection |
With commercial insurance and Lilly's savings card, orforglipron copays can drop to $25/month. Medicare Part D patients may access it for $50/month starting July 2026.
But without insurance, compounded semaglutide from a telehealth provider still delivers more weight loss per dollar spent. And compounded tirzepatide or retatrutide produce significantly greater results at similar or modestly higher price points.
Who Should Consider Orforglipron
- Needle-averse patients who refuse injections entirely
- Maintenance therapy after reaching target weight on injectable semaglutide or tirzepatide (the ATTAIN-2 trial confirmed weight maintenance when switching)
- Insured patients where the $25/month copay undercuts compounded options
- Travel-heavy lifestyles where daily pills are easier than cold-chain injectable storage
Who Should Stick with Injectable Peptides
- Anyone prioritizing maximum weight loss -- injectable semaglutide, tirzepatide, and retatrutide all outperform orforglipron
- Uninsured/self-pay patients where compounded injectables offer better value
- Patients already responding well to their current protocol -- switching introduces unnecessary variables
Where to Source Compounded GLP-1 Peptides
If you are staying with injectables, here are the current options for sourcing quality-tested peptides:
Top Semaglutide Vendors
Ranked by price, COA availability, and reputation
Top Tirzepatide Vendors
Ranked by price, COA availability, and reputation
